Development of small molecule OGG1 Inhibitor and proof of concept in bleomycin-induced disease model of Inflammation and pulmonary Fibrosis

Project description

A molecular inhibitor against pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive condition characterised by pathological inflammation and scarring in the lungs. The causes of IPF are unknown, and there is no cure, with most patients surviving approximately three years after diagnosis. Scientists of the EU-funded DOIIF project had previously developed an inhibitor of the OGG1 enzyme, which is implicated in DNA repair during oxidative stress. Since inhibition of OGG1 seems to reduce inflammation and fibrosis and slow down IPF, researchers aim to take a lead compound through preclinical development and clinical phase 1/2a for further commercialisation.

Fields of science

• medical and health sciences › health sciences › public and environmental health › epidemics prevention › immunisation

Programme(s)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)

Topic(s)

• ERC-2020-POC - Call for proposals for ERC Proof of Concept Grant

Call for proposal

ERC-2020-PoC
See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

KAROLINSKA INSTITUTET

Address

Nobels Vag 5
17177 Stockholm
Sweden

Activity type

Higher or Secondary Education Establishments

EU contribution

€ 150 000

Beneficiaries (1)

KAROLINSKA INSTITUTET

Sweden

EU contribution

€ 150 000

Address

Nobels Vag 5
17177 Stockholm

Activity type

Higher or Secondary Education Establishments